# McKesson (MCK) — Earnings

MCK · NYSE · Stock

Canonical page: https://www.lighthorse.io/tickers/mck/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q1 2027 |
| Period end | Jun 30, 2026 |
| EPS actual | $9.93 |
| EPS estimate | $9.56 |
| EPS surprise | +3.86% |
| Revenue surprise | +1.45% |
| Revenue | $105.4B |
| Revenue estimate | $103.9B |
| Reported | Aug 5, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/927653/000092765326000234/mck-20260630.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/f6fa8a98-bd88-98f2-856a-d4f9f6f3fc2a.html) |

McKesson reported fiscal Q1 2027 results on August 5, 2026. Earnings per share were $9.93, beating the $9.56 estimate by 3.86%. Revenue was $105.4 billion, 1.45% above the $103.9 billion consensus. Compared with fiscal Q1 2026, EPS rose about 20% from $8.26 and revenue rose about 8% from $97.8 billion.

The longer record shows steady growth. Annual EPS rose from $25.98 in fiscal 2023 to $27.42 in 2024, $33.10 in 2025 and $39.15 in 2026, about 51% higher over three years. Annual revenue grew each year too, from $276.8 billion to $403.5 billion. Fiscal Q4 was the strongest EPS quarter in three of those four years, and Q4 2026 set the high in the table at $11.69. The top revenue quarter was fiscal Q3 2026 at $106.2 billion. Over the last 20 quarters, McKesson beat EPS estimates 17 times. The three misses were all within 3.32%, and the largest beat was 31.97% in fiscal Q2 2022.

McKesson reported fiscal Q2 between November 1 and November 6 in each of the past five years. That points to early November 2026 for the next report. It will show whether the year-over-year growth of fiscal Q1 continues into the second quarter.

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q1 2027 | Aug 5, 2026 | $9.56 | $9.93 | 3.86% | $103.9B | $105.4B |
| Q4 2026 | May 7, 2026 | $11.56 | $11.69 | 1.08% | $101.3B | $96.3B |
| Q3 2026 | Feb 4, 2026 | $9.17 | $9.34 | 1.82% | $105.8B | $106.2B |
| Q2 2026 | Nov 5, 2025 | $9.03 | $9.86 | 9.20% | $104.1B | $103.2B |
| Q1 2026 | Aug 6, 2025 | $8.14 | $8.26 | 1.48% | $96.2B | $97.8B |
| Q4 2025 | May 8, 2025 | $9.83 | $10.12 | 2.98% | $94.3B | $90.8B |
| Q3 2025 | Feb 5, 2025 | $7.99 | $8.03 | 0.51% | $96.1B | $95.3B |
| Q2 2025 | Nov 6, 2024 | $6.88 | $7.07 | 2.75% | $89.3B | $93.7B |
| Q1 2025 | Aug 7, 2024 | $7.21 | $7.88 | 9.32% | $82.5B | $79.3B |
| Q4 2024 | May 7, 2024 | $6.36 | $6.18 | -2.81% | $79.3B | $76.4B |
| Q3 2024 | Feb 7, 2024 | $7.04 | $7.74 | 9.91% | $77.9B | $80.9B |
| Q2 2024 | Nov 1, 2023 | $6.15 | $6.23 | 1.32% | $76.0B | $77.2B |
| Q1 2024 | Aug 2, 2023 | $5.87 | $7.27 | 23.91% | $70.3B | $74.5B |
| Q4 2023 | May 8, 2023 | $7.18 | $7.19 | 0.10% | $68.1B | $68.9B |
| Q3 2023 | Feb 1, 2023 | $6.36 | $6.90 | 8.44% | $71.0B | $70.5B |
| Q2 2023 | Nov 1, 2022 | $6.09 | $6.06 | -0.45% | $70.2B | $70.2B |
| Q1 2023 | Aug 3, 2022 | $5.29 | $5.83 | 10.25% | $64.9B | $67.2B |
| Q4 2022 | May 5, 2022 | $6.03 | $5.83 | -3.32% | $63.7B | $66.1B |
| Q3 2022 | Feb 2, 2022 | $5.45 | $6.15 | 12.84% | $66.6B | $68.6B |
| Q2 2022 | Nov 1, 2021 | $4.66 | $6.15 | 31.97% | $63.2B | $66.6B |

## Frequently Asked Questions

### When did McKesson (MCK) last report earnings?

McKesson last reported on Aug 5, 2026, covering fiscal Q1 2027.

### Did MCK beat earnings estimates?

Yes. McKesson reported EPS of $9.93 for Q1 2027 against a $9.56 estimate — a 3.86% beat.

### How much revenue did MCK report last quarter?

McKesson reported $105.4B in revenue for Q1 2027, against a consensus estimate of $103.9B.

## Similar Stocks

- [AMN](https://www.lighthorse.io/tickers/amn) — AMN Healthcare Services Inc
- [HSIC](https://www.lighthorse.io/tickers/hsic) — Henry Schein, Inc. - Common Stock
- [BIO](https://www.lighthorse.io/tickers/bio) — Bio-Rad Laboratories, Inc. Class A Common Stock
- [HQY](https://www.lighthorse.io/tickers/hqy) — HealthEquity, Inc. - Common Stock
- [ITGR](https://www.lighthorse.io/tickers/itgr) — Integer Holdings Corporation Common Stock
- [WST](https://www.lighthorse.io/tickers/wst) — West Pharmaceutical Services, Inc. Common Stock
- [MMSI](https://www.lighthorse.io/tickers/mmsi) — Merit Medical Systems, Inc. - Common Stock
- [HUM](https://www.lighthorse.io/tickers/hum) — Humana Inc. Common Stock
- [CRL](https://www.lighthorse.io/tickers/crl) — Charles River Laboratories International, Inc. Common Stock
- [NEOG](https://www.lighthorse.io/tickers/neog) — Neogen Corporation - Common Stock

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).